Conclusions Based on the results of three studies, the FebriDx LFD had high diagnostic accuracy for COVID-19 in a hospital setting, however, the pooled estimates of sensitivity and specificity should be interpreted with caution due to the small number of studies included, risk of bias, and inconsistent reference standards. Further research is required to confirm these findings, and determine how FebriDx would perform in different healthcare settings and patient populations.
Different trials for different healthcare settings, proving the worth of the product. I guess?
AT1 Price at posting:
8.0¢ Sentiment: Buy Disclosure: Held
